Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17970756rdf:typepubmed:Citationlld:pubmed
pubmed-article:17970756lifeskim:mentionsumls-concept:C0034719lld:lifeskim
pubmed-article:17970756lifeskim:mentionsumls-concept:C0271650lld:lifeskim
pubmed-article:17970756lifeskim:mentionsumls-concept:C0022192lld:lifeskim
pubmed-article:17970756lifeskim:mentionsumls-concept:C1827106lld:lifeskim
pubmed-article:17970756lifeskim:mentionsumls-concept:C2917389lld:lifeskim
pubmed-article:17970756lifeskim:mentionsumls-concept:C0851287lld:lifeskim
pubmed-article:17970756lifeskim:mentionsumls-concept:C0205319lld:lifeskim
pubmed-article:17970756pubmed:issue10lld:pubmed
pubmed-article:17970756pubmed:dateCreated2008-10-2lld:pubmed
pubmed-article:17970756pubmed:abstractTextIncretin enhancers are a new class of antidiabetic drugs with promising therapeutic potential for type 2 diabetes. Therapeutic intervention in prediabetes is an attractive strategy for preventing or delaying diabetes onset. The aim of the present study was to investigate the therapeutic effects of incretin enhancement on incipient impaired glucose tolerance (iIGT) and manifest IGT (mIGT) using the dipeptidyl peptidase IV (DPP-4) inhibitor P32/98- and fatty Zucker rat (ZR, fa/fa) as a model.lld:pubmed
pubmed-article:17970756pubmed:languageenglld:pubmed
pubmed-article:17970756pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:citationSubsetIMlld:pubmed
pubmed-article:17970756pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17970756pubmed:statusMEDLINElld:pubmed
pubmed-article:17970756pubmed:monthSeplld:pubmed
pubmed-article:17970756pubmed:issn1463-1326lld:pubmed
pubmed-article:17970756pubmed:authorpubmed-author:BergSSlld:pubmed
pubmed-article:17970756pubmed:authorpubmed-author:FreyseE JEJlld:pubmed
pubmed-article:17970756pubmed:authorpubmed-author:HeinkePPlld:pubmed
pubmed-article:17970756pubmed:authorpubmed-author:SalzsiederEElld:pubmed
pubmed-article:17970756pubmed:authorpubmed-author:AltmannSSlld:pubmed
pubmed-article:17970756pubmed:authorpubmed-author:AugsteinPPlld:pubmed
pubmed-article:17970756pubmed:authorpubmed-author:DemuthH UHUlld:pubmed
pubmed-article:17970756pubmed:issnTypeElectroniclld:pubmed
pubmed-article:17970756pubmed:volume10lld:pubmed
pubmed-article:17970756pubmed:ownerNLMlld:pubmed
pubmed-article:17970756pubmed:authorsCompleteYlld:pubmed
pubmed-article:17970756pubmed:pagination850-61lld:pubmed
pubmed-article:17970756pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:meshHeadingpubmed-meshheading:17970756...lld:pubmed
pubmed-article:17970756pubmed:year2008lld:pubmed
pubmed-article:17970756pubmed:articleTitleEfficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance.lld:pubmed
pubmed-article:17970756pubmed:affiliationInstitute of Diabetes 'Gerhardt Katsch', Karlsburg, Germany. augstein@diabetes-karlsburg.delld:pubmed
pubmed-article:17970756pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17970756pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:17970756pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed